Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
-- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end --
-- Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-end--
Recent Milestones: Factor IX CB 2679d product candidate (also known as ISU304)
- Successfully completed dosing of the first and second cohorts of the Phase 1/2 clinical trial. The second cohort included the first subcutaneous dosing of individuals with hemophilia B;
- Demonstrated 22-fold higher potency and improved pharmacokinetics of CB 2679d compared with BeneFIX™ with intravenous dosing in the first patient cohort of the Phase 1/2 clinical trial in individuals with hemophilia B;
- Granted orphan drug designation for CB 2679d for the treatment of hemophilia B from the
U.S. Food and Drug Administration ; and - Received patents covering both modified Factor IX polypeptides and uses thereof for CB 2679d in
the People's Republic of China ,Singapore andTaiwan .
“We have made steady progress with the clinical development of our coagulation Factor IX hemophilia product candidate, and we look forward to presenting interim results from the ongoing Phase 1/2 subcutaneous dosing study in individuals with hemophilia B at the
Upcoming Milestones
- Present interim results from the subcutaneous Factor IX CB 2679d Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in an oral presentation on
Dec. 9, 2017 at theAmerican Hematological Society Conference inAtlanta, GA ; - Initiate the Factor VIIa marzeptacog alfa (activated) Phase 2 part of a Phase 2/3 subcutaneous efficacy clinical trial in individuals with hemophilia A or B with an inhibitor by the end of 2017;
- Announce top-line multi-dose results from the subcutaneous Factor IX CB 2679d Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B by Q1 of 2018; and
- Announce interim results from the Factor VIIa marzeptacog alfa (activated) Phase 2 clinical trial in individuals with hemophilia A or B with an inhibitor in the first half 2018.
Third Quarter 2017 Financial Highlights
- Cash, cash equivalents and short-term investments, as of
Sept. 30, 2017 , were$27.5 million . The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months. - Research and development expenses for the three months ended
Sept. 30, 2017 were$3.8 million , compared with$3.4 million for the prior year period. The increase was due primarily to manufacturing expenses for marzeptacog alfa (activated), partially offset by a decrease in personnel-related costs and a decrease in lab supply and facility costs. - General and administrative expense was
$2.4 million for both the three months endedSept. 30, 2017 and 2016. - Net loss attributable to common stockholders for the three months ended
Sept. 30, 2017 was$5.8 million , or($1.34) per basic and diluted share, compared with$4.8 million , or($6.04) per basic and diluted share, for the prior year period.
About
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia.
For more information, please visit www.catbio.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, the potential uses and benefits of CB 2679d and marzeptacog alfa (activated) and development plans for these product candidates are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Catalyst’s clinical trial timelines, including the initiation of a Phase 2/3 efficacy trial for marzeptacog alfa (activated) in 2017, the anticipated announcement of top-line results from the subcutaneous CB 2679d Phase 1/2 proof-of-concept trial by the first quarter of 2018, the anticipated announcement of interim results from the marzeptacog alpha (activated) Phase 2 clinical trial in the first half of 2018, potential uses and benefits of subcutaneously dosed marzeptacog alfa (activated) or CB 2679d, and the Company’s belief regarding sufficiency of its existing capital resources to meet its projected operating requirements for at least the next 12 months. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including, but not limited to, the risk that clinical trials and studies may be delayed and may not have satisfactory outcomes, that potential adverse effects may arise from the testing or use of Catalyst’s products, the risk that costs required to develop or manufacture Catalyst’s products will be higher than anticipated, competition and other factors that affect our ability to successfully develop and commercialize our product candidates, and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the
Contacts:
Investors:
1.650.871.0761
investors@catbio.com
Media
LifeSci Public Relations
1.646.751.4361
jo@lifescipublicrelations.com
| Catalyst Biosciences, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| September 30, 2017 | December 31, 2016 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 10,973 | $ | 10,264 | ||||
| Short-term investments | 16,477 | 6,800 | ||||||
| Restricted cash | 5,727 | 19,468 | ||||||
| Accounts receivable | 52 | 31 | ||||||
| Prepaid and other current assets | 849 | 958 | ||||||
| Total current assets | 34,078 | 37,521 | ||||||
| Restricted cash, noncurrent | — | 125 | ||||||
| Property and equipment, net | 315 | 444 | ||||||
| Total assets | $ | 34,393 | $ | 38,090 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,460 | $ | 837 | ||||
| Accrued compensation | 920 | 596 | ||||||
| Other accrued liabilities | 1,095 | 805 | ||||||
| Deferred revenue, current portion | 530 | 283 | ||||||
| Deferred rent, current portion | 18 | 41 | ||||||
| Redeemable convertible notes | 5,488 | 19,403 | ||||||
| Total current liabilities | 9,511 | 21,965 | ||||||
| Deferred revenue, noncurrent portion | — | 47 | ||||||
| Deferred rent, noncurrent portion | — | 7 | ||||||
| Total liabilities | 9,511 | 22,019 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; 5,500 and 0 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | — | — | ||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized; 4,310,561 and 801,756 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 4 | 1 | ||||||
| Additional paid-in capital | 192,615 | 164,053 | ||||||
| Accumulated other comprehensive income (loss) | 4 | (1 | ) | |||||
| Accumulated deficit | (167,741 | ) | (147,982 | ) | ||||
| Total stockholders’ equity | 24,882 | 16,071 | ||||||
| Total liabilities and stockholders’ equity | $ | 34,393 | $ | 38,090 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| Catalyst Biosciences, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Contract revenue | $ | 318 | $ | 109 | $ | 700 | $ | 328 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 3,805 | 3,396 | 9,286 | 8,443 | ||||||||||||
| General and administrative | 2,391 | 2,425 | 7,407 | 7,083 | ||||||||||||
| Total operating expenses | 6,196 | 5,821 | 16,693 | 15,526 | ||||||||||||
| Loss from operations | (5,878 | ) | (5,712 | ) | (15,993 | ) | (15,198 | ) | ||||||||
| Interest and other income, net | 85 | 941 | 185 | 2,003 | ||||||||||||
| Net loss | (5,793 | ) | (4,771 | ) | (15,808 | ) | (13,195 | ) | ||||||||
| Deemed dividend for convertible preferred stock beneficial conversion feature | - | — | (3,951 | ) | — | |||||||||||
| Net loss attributable to common stockholders | $ | (5,793 | ) | $ | (4,771 | ) | $ | (19,759 | ) | $ | (13,195 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (1.34 | ) | $ | (6.04 | ) | $ | (6.49 | ) | $ | (17.10 | ) | ||||
| Shares used to compute net loss per share attributable to common stockholders, basic and diluted | 4,310,561 | 789,796 | 3,043,919 | 771,713 | ||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
